Research Education Component

$247,715P30FY2025AGNIH

Emory University, Atlanta GA

Investigators

Linked publications & trials

Paper 39677464 Paper 39649607 Paper 39640424 Paper 39554163 Paper 39535480 Paper 39503843 Paper 39496718 Paper 39496102 Paper 39484566 Paper 39483910 Paper 39444005 Paper 39434503 Paper 39428957 Paper 39405331 Paper 39380021 Paper 39371140 Paper 39365322 Paper 39352226 Paper 39294787 Paper 39281731 Paper 39281728 Paper 39276722 Paper 39215503 Paper 39195563 Paper 39185475 Paper 39169269 Paper 39137265 Paper 39127040 Paper 39055313 Paper 38974877 Paper 38965435 Paper 38943387 Paper 38924699 Paper 38924596 Paper 38903124 Paper 38896163 Paper 38859733 Paper 38858522 Paper 38788065 Paper 38780681 Paper 38759012 Paper 38755756 Paper 38753380 Paper 38746455 Paper 38746437 Paper 38713744 Paper 38712073 Paper 38712030 Paper 38680829 Paper 38659743 Paper 38612775 Paper 38612729 Paper 38601333 Paper 38598986 Paper 38574399 Paper 38559129 Paper 38553838 Paper 38526701 Paper 38520489 Paper 38507374 Paper 38464223 Paper 38464214 Paper 38460116 Paper 38425134 Paper 38390561 Paper 38380866 Paper 38374692 Paper 38364295 Paper 38353367 Paper 38345347 Paper 38312309 Paper 38308693 Paper 38306056 Paper 38302557 Paper 38301647 Paper 38298163 Paper 38296755 Paper 38260316 Paper 38260284 Paper 38243325 Paper 38234807 Paper 38230729 Paper 38222248 Paper 38216151 Paper 38184787 Paper 38166254 Paper 38066663 Paper 38053483 Paper 38040087 Paper 38038976 Paper 38034852 Paper 38014176 Paper 38014121 Paper 37986771 Paper 37985223 Paper 37984431 Paper 37966908 Paper 37954546 Paper 37954510 Paper 37944004

Abstract

Project Summary Alzheimerâs disease (AD) is the most common cause of dementia, affecting more than 5 million Americans. At the same time that the prevalence of AD is increasing, the number of new investigators in the US is decreasing, which may severely hamper our efforts to develop better diagnostic and treatment tools for AD and related dementias (ADRD). During its initial 5 years of existence, the Research Education Component (REC) successfully recruited and trained 20 diverse participants (30% URM) who demonstrated outstanding scholarly productivity and career advancement in the ADRD field. The REC will continue to support the overall goals of the Goizueta Alzheimerâs Disease Research Center (GADRC) by fostering innovative research and training activities focused on discovering and translating new ADRD therapeutic targets, interventions, biomarkers, pathogenic mechanisms, precision medicine and multi-etiology dementia. We will achieve this goal by identifying and supporting the research education of junior investigators and trainees from diverse backgrounds and disciplines. In Aim 1, REC leadership and mentors will work with these trainees to develop and execute tailored educational plans for new and early stage investigators to advance towards independence in conducting ADRD research. In Aim 2, we will leverage Emoryâs wealth of basic and clinical scientists as well as partner Atlanta- area institutions to identify, recruit and support the research training of new/early stage investigators and trainees from diverse backgrounds and disciplines, with special emphasis on URMs, to engage in ADRD research. In Aim 3, the REC leadership will partner with GADRC leadership, External Advisory Committee, and the Emory Training Grant Support Office to rigorously monitor and evaluate the trainees, mentors, and the overall program, and implement improvements when necessary. Success of the REC will result in rolling cohorts of new investigators with a focus on diversity to lead the next generation of ADRD research.

View original record on NIH RePORTER →